Výsledky vyhledávání - "A K, Parsons"

Akademický článek

Evaluating the Safety and Efficacy of Telemedicine Physician Assessments on a Mobile Stroke Unit: Protocol for a Prospective Open‐Label Blinded End‐Point Randomized Controlled Trial

Autor: Vignan Yogendrakumar, Anna H. Balabanski, Hannah Johns, Leonid Churilov, Nicola K. Parsons, James Beharry, Louise Weir, Nawaf Yassi, Henry Zhao, Alex Warwick, Skye Coote, Francesca Langenberg, Leigh Branagan, Wasseem Siddiqi, Andrew Bivard, Bruce C. V. Campbell, Geoffrey A. Donnan, Stephen M. Davis

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 21 (2024)

Background Mobile stroke units have been shown to deliver faster patient care and improve clinical outcomes. However, costs associated with staffing limit their use to densely populated cities. Using the Melbourne mobile stroke unit, we aim to evalua

Externí odkaz: https://doaj.org/article/40ce316dacf14ec9b7426da63e6b4e18

Zobrazit plný text záznamu

Akademický článek

Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial

Autor: Suzanne Braniecki, Elliott Vichinsky, Mark C. Walters, Shalini Shenoy, Qiuhu Shi, Theodore B. Moore, Julie-An Talano, Susan K. Parsons, Allyson Flower, Anne Panarella, Sandra Fabricatore, Erin Morris, Harshini Mahanti, Jordan Milner, Robert C. McKinstry, Christine N. Duncan, Carmella van de Ven, Mitchell S. Cairo

Publikováno v: Frontiers in Neurology, Vol 15 (2024)

BackgroundDue to the risk of cerebral vascular injury, children and adolescents with high-risk sickle cell disease (SCD) experience neurocognitive decline over time. Haploidentical stem cell transplantation (HISCT) from human leukocyte antigen-matche

Externí odkaz: https://doaj.org/article/1ffd73bb5fe045e7b11a68a31f21a4a3

Zobrazit plný text záznamu

Review

Bat surveys - good practice guidelines K. Parsons R. Crompton R. Graves S. Markham J. Matthews M. Oxford P. Shephard S. Sowler

Autor: Sleeman, Paddy

Publikováno v: The Irish Naturalists' Journal, 2008 Sep 01. 29, 74-74.

Externí odkaz: https://www.jstor.org/stable/20764447

Zobrazit plný text záznamu

Akademický článek

Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group AHOD 1331 study

Autor: Susan K. Parsons, Angie Mae Rodday, Qinglin Pei, Frank G. Keller, Yue Wu, Tara O. Henderson, David Cella, Kara M. Kelly, Sharon M. Castellino

Publikováno v: Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-12 (2023)

Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is an under-recognized complication of several chemotherapy agents used as part of curative-intent therapy for Hodgkin Lymphoma (HL). In the absence of validated self- or proxy-rep

Externí odkaz: https://doaj.org/article/dae90ca588e241778004915435ffdab9

Zobrazit plný text záznamu

Akademický článek

Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data

Autor: Priyanka A. Pophali, Lindsay M. Morton, Susan K. Parsons, David Hodgson, Gita Thanarajasingam, Carrie Thompson, Thomas M. Habermann, Kerry J. Savage

Publikováno v: eJHaem, Vol 4, Iss 4, Pp 927-933 (2023)

Abstract Adolescents and young adults (AYA) with lymphoma experience treatment‐related effects in the short and long term that impact their quality of life and survivorship experience. The effort to improve outcomes for AYA lymphoma survivors requi

Externí odkaz: https://doaj.org/article/61d1b8ed2b744507ae4ac97bfef1f3a4

Zobrazit plný text záznamu

Akademický článek

The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer

Autor: Xiao Hu, Jeffrey H. Lin, Stacey Pan, Yana V. Salei, Susan K. Parsons

Publikováno v: Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100833- (2024)

Background: The data on immune checkpoint inhibitors (ICI) use in lung cancer individuals generally underrepresented in clinical trials are limited. We aimed to examine the ICI access, safety, and outcome in these populations using real-world data. M

Externí odkaz: https://doaj.org/article/0ac80a89967d44749331bf0a892c109f

Zobrazit plný text záznamu